1049.3000 12.30 (1.19%)
NSE Sep 18, 2026 15:31 PM
Volume: 2.1M
 

1049.30
1.19%
Anand Rathi
Max Healthcare posted a stable performance in Q1FY27, with revenue/EBITDA/PAT rising by 15/15/4% y/y. Consolidated revenue grew 15% y/y to Rs28.3bn (ex-Onco up 20% y/y), while Max Labs/Max@Home revenue came in at Rs580/780m (up 20/32% y/y).
Max Healthcare Institute Ltd. is trading above all available SMAs
More from Max Healthcare Institute Ltd.
Recommended